INTRODUCTION
Influenza is an infectious disease caused by RNA viruses of the
Orthomyxoviridae family. Influenza A viruses (IAVs) originate from wild aquatic birds and circulate among several other species, including chickens, pigs, and humans. The animal reservoir is a never-ending source of viruses that spill over to humans, causing mainly sporadic, self-limiting infections with minimal evidence of human-to-human transmission (
1). Episodically, however, zoonotic IAVs evolve into pandemic strains which spread globally, causing significant death and illness. In general, an influenza pandemic occurs when most of the human population has no immunological memory against the emerging IAV strain (
2); however, preexisting and cross-reactive immunity can prevent or attenuate the infection of the newly introduced virus in some sections of the population (
3,
4). Pandemic viruses subsequently evolve into seasonal, human-adapted viruses, and “herd” immunity becomes established (
5).
To efficiently replicate in the new host, pandemic IAVs must counteract a number of host restriction factors (RFs) that are mostly inducible by type I interferons (IFNs) produced during the early phase of the infection (
6,
7). Among the most potent and best characterized type I IFN-stimulated genes (ISGs), the MxA gene encodes a dynamin-like large GTPase that recognizes the viral ribonucleoprotein (vRNP) complex, thereby blocking its function (
8). Interestingly, it has been shown that while avian IAVs are generally highly sensitive to MxA restriction, pandemic strains escape MxA restriction through adaptive mutations in the viral nucleoprotein (NP) (
9,
10). Another ISG, coding for the 3′-to-5′ exoribonuclease ISG20, was shown to inhibit IAV replication by interacting with NP (
11). These observations suggest that NP is a major target of IFN-induced RF.
Accordingly, we have shown previously that tripartite motif 22 (TRIM22), a member of the large family of TRIM proteins, restricts IAV infection by interacting with the NP of seasonal viruses, thereby promoting its ubiquitination and proteasomal degradation (
12). Here, we report that the 2009 pandemic H1N1 strain, as well as two IAV strains isolated in 1933 and 1934 that derive from the 1918 pandemic virus, are resistant to TRIM22 restriction. Sequence alignment revealed the presence of four arginine residues in the NP of TRIM22-resistant viruses instead of four lysine residues present in TRIM22-susceptible ones. All of these lysines are solvent exposed in the available NP crystal structure and therefore can serve as ubiquitin acceptor sites through the E3 ubiquitin ligase activity of TRIM22. Overall, our study provides a novel molecular signature for IAVs that are long established in the human population, which is, unexpectedly, associated with increased susceptibility to TRIM22-mediated restriction.
DISCUSSION
We report here that the 2009 pandemic H1N1 virus as well as the WSN and PR8 strains, derived from the 1918 pandemic virus, are resistant to TRIM22 restriction, in contrast to what was observed for seasonal H1N1 strains that are inhibited by TRIM22. As TRIM22 targets the viral NP for polyubiquitination (
12), we analyzed the numbers and sites of NP lysine residues in a large number of viral isolates of the IRD. We have identified four lysine residues (i.e., K98, K293, K422, and K446) that are potentially associated with sensitivity of seasonal IAV to TRIM22 restriction; in contrast, the pandemic strains are characterized by four arginine residues at the same sites in NP. Our data suggest that the progressive substitution of these lysine residues during prolonged IAV circulation in the human population is associated with increased sensitivity to TRIM22 restriction that is mediated by TRIM22 polyubiquitination and degradation of NP.
Successful establishment of pandemic IAV occurs when the newly introduced virus is efficiently transmitted from infected humans to humans immunologically naive (
2). The selective advantage conferred by the new antigenicity often leads to the replacement of the formerly circulating seasonal IAV (
22). Although innate and adaptive immune responses reduce serious illness and constrain the virus to progressively acquire features of annual seasonal strains (
23), IAVs continuously evolve under natural and selective pressure of the host immune response (
1). The IAV proteins that mostly accumulate selective mutations are the surface glycoproteins hemagglutinin (HA) and neuraminidase (NA), which are the main targets of the humoral response (
24,
25). In addition, IAV internal genes are also under selective pressure of the adaptive immune response. In this regard, NP is a highly conserved (≈90%) internal IAV protein that nevertheless shows adaptive amino acid changes (
16,
26). Indeed, most of the IAV immunodominant cytotoxic T lymphocyte (CTL) epitopes are located in NP (
27); conversely, several amino acid substitutions of NP have been reported to correlate with the viral escape from the CTL response (
28). Furthermore, comparison of CTL epitopes in human versus swine NP clearly indicates that human IAVs evolve under positive selection (
29). Notably, two of the four NP residues that determine the sensitivity to TRIM22 (residues 98 and 422) are part of CTL epitopes, suggesting that the R98K and R422K mutations, which occurred earlier than R293K and R446K, may have been driven by the evasion of T-cell-mediated immunity. However, as residues 293 and 446 are not part of CTL epitopes, we cannot exclude other hypotheses, such as a positive selection of R-to-K substitutions driven by selection factors that are not related to T-cell-mediated immunity (e.g., increased sensitivity to TRIM22, by contributing to the attenuation of the virus, could indirectly favor viral spread) and/or a stochastic selection based on successive population bottlenecks.
The recombinant virus expressing sH1N1 NP lost TRIM22 restriction when all four lysine residues were replaced by arginine residues (R4 mutant), whereas three lysine-to-arginine changes at sites 98, 293, and 422 did not cause loss of TRIM22 restriction (data not shown), in contrast with the results obtained in the polymerase activity assay, (
Fig. 5B), where the same substitutions caused loss of TRIM22 restriction. As four mutations are necessary to confer TRIM22 sensitivity in the viral growth assay, a partial discrepancy emerges by comparing it with the polymerase activity assay, in which only two mutations are enough to highlight an effect of TRIM22. These differences are likely explained by an intrinsic limitation of the polymerase activity assay to study the entire IAV life cycle (
30,
31).
Notably, all four NP lysines required for TRIM22 restriction are exposed to the solvent and potentially accessible to its E3 ubiquitin ligase activity. Our previous work (
12) and the present study have identified TRIM22 as an E3 ubiquitin ligase that promotes polyubiquitination of NP, therefore, causing its downregulation and inhibition of viral replication (
Fig. 7). In addition, a recent independent report has shown that NP is endowed with multiple lysine residues that are sites of monoubiquitination by the CNOT4 (Ccr4-Not transcription complex subunit 4) protein (
32). The same investigators have reported that NP is also a target of deubiquitinating enzymes such as USP11 (
33). According to these studies, NP monoubiquitination plays a positive role in NP stability and overall polymerase function (
33,
34). In this regard, it should be emphasized that the four lysine residues sensitive to TRIM22 polyubiquitination may not be a target of CNOT4 activity; however, it should be taken into account that CNOT4 activity was studied in the A/WSN/33 strain, which is insensitive to TRIM22 restriction and is characterized by four arginine residues at sites 93, 293, 422, and 446 (
32). Nevertheless, both our and these independent results highlight the fact that IAV exploits the cellular ubiquitination machinery to either promote or limit viral replication. Of note, none of the amino acid variations observed in our study are involved in the conserved functional regions of NP, including the unconventional nuclear localization signal (NLS [residues 4 to 14]) and the bipartite NLS (residues 198 to 216) (
35), binding to viral RNA (residues 73 to 91) (
18) and viral polymerase (R204, W207, and R208) (
36).
In contrast to TRIM22, MxA has been shown to be effective against avian strains, but not against seasonal viruses (
9,
10). Interestingly, signatures of MxA resistance are present in NP of the 2009 pandemic H1N1 strain (
10,
37). However, MxA escape mutations, which are a hallmark of all IAVs circulating in humans (
10), initially caused a significant loss of viral fitness and were compensated for by the subsequent acquisition of additional mutations (
37). Deep mutational scanning in MDCK cells expressing MxA has recently highlighted additional mutations that confer some level of MxA resistance and are conserved across human and avian influenza viruses (
38). In order to explain these results, the authors have proposed that homologs of MxA in other hosts have selected some level of generalized MxA resistance in all NPs (
38). However, an important difference between TRIM22 and MxA is the lack of
TRIM22 orthologs in avian and swine hosts (
39). In addition to intrinsic innate immune differences between swine and human hosts, a recent analysis of NP evolution of the swine viral lineage has highlighted that swine influenza virus is not under the selection of CD8
+ T cells and immune memory as pigs are infected only once or a few times during their short lives (
29). Of note is the conservation of these four arginine residues (R98, R293, R422, and R446) in avian and swine NP (
16,
17), supporting the importance of arginine-to lysine substitutions during IAV adaptation in the human host to endow the virus with TRIM22 restriction.
In conclusion, we have discovered that four arginine residues that were present in NP of seasonal H1N1 viruses in the 1930s evolved with time into lysines, leading to the acquisition of TRIM22-dependent inhibition of virus replication. Thus, this analysis has contributed to improving our understanding of NP genotype-to-phenotype mapping and in highlighting the complexity of the selective pressures acting on the NP, as adaptive changes inside but also outside CTL epitopes can be favored at the expense of increased sensitivity to some factors of the innate immune response to IAV infection.
MATERIALS AND METHODS
Cells and viruses.
HEK293T cells and Madin-Darby canine kidney (MDCK) cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with glutamine (2 mmol/liter), penicillin (100 U/ml), streptomycin (100 U/ml), and 10% fetal bovine serum (FBS) (complete DMEM; Thermo Fisher Scientific, Inc.).
TRIM22-overexpressing MDCK cells were kindly provided by G. Towers (UCL, London, United Kingdom). Briefly, cells were transduced twice with a retroviral vector expressing TRIM22 (pEXN-HA-TRIM22) at 24-h intervals, replacing culture medium with vector-containing supernatant at a 1:1 ratio. MDCK control cells were transduced with an empty vector (pEXN-HA-empty). Seventy-two hours after the second transduction, cells were subjected to selection with G418 (3 mg/ml; Sigma-Aldrich).
Influenza virus strains A/WSN/33 (H1N1), A/PR/8/34 (H1N1), and A/Paris/7608/2009 (H1N1) were obtained by a reverse-genetics system. Other viruses were provided by the National Reference Center for Influenza Viruses at Institut Pasteur, Paris, France.
IAV propagation and titration.
Monolayers of MDCK cells were washed twice with DMEM without serum and infected with H1N1 viruses at a multiplicity of infection (MOI) of 0.001. After virus adsorption for 1 h at 35°C, cells were washed twice and incubated at 35°C with DMEM without serum supplemented with tosylsulfonyl phenylalanyl chloromethyl ketone (TPCK)-treated trypsin (1 µg/ml; Worthington Biomedical Corporation). Supernatants were recovered 48 hpi.
For viral titration, a plaque assay was performed as previously described (
12). Briefly, MDCK monolayer cells, seeded in 6-well plates at 1.2 × 10
6/well, were washed twice with DMEM without serum, and serial dilutions of virus were adsorbed onto cells for 1 h. Cells were covered with MEM 2×-Avicel (FMC Biopolymer) mixture supplemented with TPCK-treated trypsin (1 µg/ml). Crystal violet staining was performed 48 hpi, and visible plaques were counted.
Polymerase activity assay.
HEK293T cells (3 × 10
4/well) were seeded into a 96-well plate. After 24 h, cells were transfected with a mixture of 4 plasmids encoding the components of the viral RNA polymerase complex (PB1, PB2, and PA [20 ng/each] plus NP [40 ng]) of the 2009 pandemic H1N1 strain under the promoter of the 3-hydroxy-3-methylglutaryl (HMG) coenzyme A reductase constitutively expressed in all cell types (
40). In addition, plasmid pPR7-FluA-
Renilla (5 ng), which encodes the viral minigenome, and a control plasmid expressing the firefly luciferase driven by the cytomegalovirus (CMV) promoter (5 ng) were included in the transfection mixture. To evaluate TRIM22 interference on virus-dependent transcription, HEK293T cells were cotransfected with increasing amounts of TRIM22-expressing plasmid. Cell lysates were harvested 48 h posttransfection.
Renilla and firefly luciferase activities were determined using the Dual-Glo luciferase assay (Promega) according to the manufacturer’s instructions. Untransfected control cells were used to obtain the basal background.
In silico analysis.
NP sequences of different human IAV H1N1 strains were analyzed using the IRD (
http://www.fludb.org) of the U.S. National Institute of Allergy and Infectious Diseases through the Bioinformatics Resource Centers Program (last accessed 13 November 2016). NP sequences of each viral subtype were aligned using the MUltiple Sequence Comparison by Log-Expectation (MUSCLE) algorithm. The phylogenetic analyses were conducted with Molecular Evolutionary Genetics Analysis (MEGA;
http://www.megasoftware.net). Bootstrap analysis was performed with 1,000 replications.
Molecular modeling.
The three-dimensional (3D) model of the mutant form of NP, with 4 R-to-K single-point mutations at sites 98, 293, 422, and 446 (NPR4/K4), was generated using as the templates the crystallographic structure of the influenza A virus NP (PDB codes
2IQH [
18] and
4BBL [
21]). Models and missing loops were generated using the Swiss-model web server (
https://swissmodel.expasy.org/) (
41). Structures were then refined with the Protein Preparation Wizard available in the Maestro software package (
42). Hydrogens were added, the orientations of the hydroxyl groups of serine, threonine, and tyrosine were obtained, and the side chains of asparagine and glutamine residues were optimized. The protonation states were chosen according to the neutral pH, and a minimization employing an opls 2005 force field with a root mean square deviation (RMSD) tolerance on heavy atom of 0.3 Å was performed. To evaluate the accessibilities of the four lysines (K98, K293, K422, and K446), we calculated the solvent-accessible area using Naccess V2.1.1 (
43).
Generation of recombinant IAVs.
The pandemic A/Paris/2590/2009 H1N1 strain was used in this study. WT pandemic virus was generated by reverse genetics using 8 bidirectional plasmids as previously described (
44). NP mutant virus was generated by reverse genetics using a 9-plasmid reverse-genetics system, consisting of 7 bidirectional plasmids from the WT pandemic system, one monodirectional sH1N1 NP pPolI plasmid, which is in a negative orientation, and the pcDNA of the pH1N1 NP plasmid to increase the efficiency of reverse genetics. WT and mutant sH1N1 NP Ppr7 plasmids were synthetized by GenScript. Viruses were generated by 1-day coculture of HEK293T and MDCK cells (seeded at 3 × 10
5 and 4 × 10
5 cells, respectively, in 6-well plates) transfected with the plasmid mixture (0.5 µg per plasmid) using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s recommendations. After 3 days, cell supernatants were harvested and clarified by low-speed centrifugation (2 min at 2,600 ×
g for 2 min at 4°C) and used to inoculate MDCK cells for 48 h for the amplification of rescued viral stocks. Viral titer was determined on MDCK cells by plaque assay. The virus NP gene was sequenced to validate the presence of the mutations.
Site-directed mutagenesis.
To insert site-specific mutations in NP, site-directed mutagenesis was performed by using the QuikChange site-directed mutagenesis kit (Agilent). The arginine residues at sites 98, 293, 422, and 446 of pH1N1 NP were mutagenized into lysine residues, whereas sH1N1 NP was mutagenized to change lysine into arginine residues at the same positions. PCR amplification was performed using specific primer pairs. To fulfill the mutagenesis requirements, the primer pairs were designed to contain the desired mutation with a melting temperature (Tm) of ≥68°C. The primer pairs were annealed to NP pcDNA3.1(+) plasmid.
Western blot.
Whole-cell extract (WCE) from MDCK and HEK293T cells was prepared as previously described (
12). Samples were run on SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to nitrocellulose membrane by electroblotting. Filters were incubated with either a rabbit polyclonal Ab raised against TRIM22 (
45) or an anti-NP monoclonal antibody (MAb; Southern Biotech). An anti-β-actin MAb (Sigma-Aldrich) was used as a control. Quantification of bands was performed by using ImageJ software (version 1.47v, WS Rasband ImageJ, NIH;
http://rsb.info.nih.gov).
Ubiquitination assay.
WT and mutant pH1N1 NP coding sequences were cloned from pcDNA3.1(+) into p3×Flag-Myc-CMV-26 plasmid (Sigma-Aldrich). Transient-transfection experiments were performed in HEK293T cells in 100-mm cell culture dishes using the calcium phosphate method (2 µg of Flag-NP plus 4 µg of His-Ubi plus 4 µg of TRIM22). Forty-eight hours after transfections, cells were treated with 10 µM MG132 for 3 h. Cells were washed twice in phosphate-buffered-saline (PBS) and resuspended in lysis buffer (20 mM Tris-HCl [pH 8], 10 mM NaF, 1 mM EDTA, 150 mM NaCl, 1 mM dithiothreitol [DTT], 100 µM phenylmethylsulfonyl fluoride [PMSF], phosphatase, and protease inhibitor cocktail [1 tablet/10 ml; Roche Diagnostics], 10% glycerol, 1% NP-40). For Ni-NTA (Qiagen) pulldown experiments, WCE was prepared from a 10% fraction of the cells and analyzed by Western blotting for the expression of transfected proteins. The remaining 90% of the cells were lysed in a denaturing buffer (6 M guanidine-HCl, 100 mM Na2HPO4/NaH2PO4 [pH 8.0], 10 mM Tris-HCl [pH 8.0], 0.2% Triton X-100), and ubiquitinated proteins were precipitated using Ni-NTA agarose.
Statistical analysis.
All statistical analyses were performed using Prism GraphPad Software, Inc., v.4.0 (GraphPad Software, Inc.). Comparison between two groups was performed using the unpaired t test, while two-way analysis of variance (ANOVA) with Bonferroni’s multiple comparison was used to compare more than two groups.
ACKNOWLEDGMENTS
We thank Guido Poli from the Vita-Salute San Raffaele University, Milan, Italy, and Edwin Yates from the University of Liverpool, Liverpool, United Kingdom, for critical reading of the manuscript. We thank Sylvie Behillil from the National Reference Center for Influenza Viruses, Institut Pasteur, Paris, for providing viral strains.
Isabel Pagani conducted this study as partial fulfillment of her Ph.D. in Molecular Medicine, Program in Basic and Applied Immunology, International Ph.D. School, Vita-Salute San Raffaele University, Milan, Italy.
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.